Q3 EPS Estimates for IDEAYA Biosciences Raised by Wedbush

Key Points

• Wedbush raised its earnings estimates for IDEAYA Biosciences, projecting $1.37 earnings per share for Q3 2025, up from a previous estimate of ($0.94).
• IDEAYA reported a quarterly loss of ($0.88) EPS, slightly missing analyst expectations, but achieved revenues of $6.00 million compared to a consensus of $3.48 million.
• Investment firms like JPMorgan and Goldman Sachs have recently adjusted their price targets and ratings for IDEAYA Biosciences, with the average target price now around $47.30.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Research analysts at Wedbush lifted their Q3 2025 earnings estimates for IDEAYA Biosciences in a note issued to investors on Tuesday, September 2nd. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of $1.37 for the quarter, up from their previous estimate of ($0.94). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share. Wedbush also issued estimates for IDEAYA Biosciences' FY2025 earnings at ($1.29) EPS, Q1 2026 earnings at ($1.03) EPS, Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($3.77) EPS, FY2027 earnings at ($3.48) EPS, FY2028 earnings at ($3.13) EPS and FY2029 earnings at ($0.77) EPS.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $3.48 million. The business's quarterly revenue was up NaN% compared to the same quarter last year. During the same period last year, the firm earned ($0.68) earnings per share.

Several other equities analysts have also recently weighed in on IDYA. Citigroup initiated coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 4th. They set an "outperform" rating for the company. JPMorgan Chase & Co. raised their target price on shares of IDEAYA Biosciences from $72.00 to $74.00 and gave the company an "overweight" rating in a research note on Wednesday, September 3rd. Royal Bank Of Canada lifted their price objective on shares of IDEAYA Biosciences from $36.00 to $38.00 and gave the stock an "outperform" rating in a research note on Tuesday. TD Cowen started coverage on shares of IDEAYA Biosciences in a research note on Tuesday, July 22nd. They issued a "buy" rating for the company. Finally, The Goldman Sachs Group raised shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective for the company in a research note on Thursday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.00.

IDEAYA Biosciences Trading Up 5.6%

IDYA traded up $1.31 during trading on Thursday, hitting $24.70. 898,372 shares of the company traded hands, compared to its average volume of 1,148,944. The company has a market cap of $2.16 billion, a PE ratio of -6.51 and a beta of 0.12. The stock's 50-day simple moving average is $23.71 and its two-hundred day simple moving average is $20.64. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $37.80.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Daiwa Securities Group Inc. lifted its holdings in IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company's stock valued at $66,000 after buying an additional 436 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of IDEAYA Biosciences by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company's stock worth $123,000 after acquiring an additional 627 shares in the last quarter. CWM LLC raised its stake in shares of IDEAYA Biosciences by 33.0% during the 2nd quarter. CWM LLC now owns 3,153 shares of the company's stock worth $66,000 after acquiring an additional 782 shares in the last quarter. E Fund Management Co. Ltd. raised its stake in shares of IDEAYA Biosciences by 7.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 12,225 shares of the company's stock worth $257,000 after acquiring an additional 881 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in IDEAYA Biosciences by 39.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company's stock worth $70,000 after purchasing an additional 940 shares during the last quarter. Institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.